



OXFORD-HARRINGTON RARE DISEASE CENTRE

ACCELERATING CURES FOR RARE DISEASES

IMPACT-DRIVEN MISSION

The Oxford-Harrington Rare Disease Centre, a partnership between the University of Oxford and Harrington Discovery Institute, is a global initiative to develop novel treatments for rare diseases, for which therapeutic options are severely lacking. **Our mission** is to deliver new treatments for the 400 million people worldwide who suffer from a rare disease. **Our goal** is aggressive; to advance 40 drugs into clinical trials in the next 10 years, targeting multiple approvals in key markets.

WORLD-LEADING STRENGTHS COMBINED



Harrington Discovery Institute

- Globally-recognized drug development model
- 177 medicines in the making
- 36 companies launched
- 19 medicines in the clinic
- 13 licenses to pharma

University of Oxford

- #1 in world for medicine
- Global research in 40 countries
- Over £416 million annual research income
- Over 8,000 research outputs per year

GLOBAL NEED

10,000+

distinct types of rare and genetic diseases

400 MILLION

people worldwide suffer from a rare disease


1 OF 2

patients diagnosed with a rare disease is a child

<5%

of rare diseases have approved treatments

ACCELERATOR MODEL



ADVANCING DISCOVERIES INTO CLINICAL TRIALS

Breakthrough Science: Promising discoveries from academic labs in the UK and US are eligible for support through the OHC. The OHC prioritizes diseases:

- That are genetic
- That affect either children or adults
- That fill an urgent need with great impact
- That fall in the areas of rare neurological diseases, cancers, and development diseases

Funding: The OHC has two funding streams.

Not-for-profit: Includes public funders, government, charities and foundations, philanthropy, industry, and Harrington Scholar grants.

For-profit: Includes Harrington venture activity, Oxford Science Enterprises and other impact investors.

Expertise: All projects receive drug development, commercial strategy and business development support from pharma-experienced industry leaders with a track record of bringing new drugs to market.



PARTNERS



Morgan Stanley | GIFT Cures

The Harrington Family

Individual Philanthropic Contributors



A Partnership of



TOGETHER WE CURE

OxfordHarrington.org